This proposal is for renewal of our postdoctoral research training grant in Immunohematology and Transfusion Medicine that was initiated in 2001. The six position program provides a highly organized 2-3 year experience of focused dedicated didactics, seminars, and, most importantly, an intense research experience with one of 29 well-established, highly interactive, and well-funded cross-disciplinary mentors representing eight different primary departments. The goal is to generate productive MD and MD/PhD physician- scientists as well as PhD scientists and clinician-scientists, who will be launched on a lifelong investigative career pursuing basic, translational, and clinical research in this relatively underrepresented field. Careful career development by an individualized Training and Career Advisory Committee is a hallmark of the program. Two major degree- granting tracks are also available in addition to the core post-doctoral program: an Investigative Medicine PhD available to MD-only trainees who wish to obtain a more expansive research background mimicking that of an MD/PhD; and a Masters of Biomedical Engineering for trainees with a past basic biomedicine emphasis who wish to add a diagnostic and cellular therapeutic engineering dimension to their knowledge base. Drawn from an MD, MD/PhD, and PhD candidate pool focused on those whose background is Laboratory Medicine & Pathology (a pool which has always included at least 10 fold more excellent, training grant eligible, candidates than can be accepted into the T32 program), outcomes have been quite positive. Of the 21 graduates of the T32 program over 15 years, there was an average of 4.2 papers and 2.2 first-author papers per trainee published as a direct result of the T32 training and all 21 graduates have published papers in the last three years as a result of their continuing scientific careers. All are in scientific careers; 48% are in tenure-track research-intensive positions at research universities; 19% in careers on the ladder research track at major universities, and 21% are in senior scientist positions in industry. The core T32 is leveraged, that is, the entire enrollment in the Laboratory Medicine Departmental Immunohematology-Transfusion Medicine research training program is greater than the T32-funded individuals alone by about 50%, since the extended program includes individuals on other funding mechanisms sharing the same infrastructure. Including trainees in the extended program, there are 63% University tenure-track faculty, 13% University research track faculty, and 19% in senior scientist positions in industry. As the only benign hematology T32 at Yale, one of the few Immunohematology T32s in the country that emphasizes PhD clinician-scientists along with MD and MD/PhD physician-scientists, and also one of the few postdoctoral hematology T32s that includes bioengineering and PhD degree tracks, this program fills an important research training need both at Yale and nationally.
The newly emerging areas of stem cell biology, cell based therapies, gene therapy, cellular immunology, recombinant cytokines, and improving the safety and efficacy of transfused blood components have potential for the improvement of transfusion practices and the management of hematologic diseases. Thus, it is critical to train the next generation of investigators who can conduct basic, translational, and clinical research in Immunohematology and Transfusion Medicine. This proposed program renewal, with a 15 year successful history, aims to accomplish these goals.
| Hauser, Ronald George; Quine, Douglas B; Ryder, Alex (2018) LabRS: A Rosetta stone for retrospective standardization of clinical laboratory test results. J Am Med Inform Assoc 25:121-126 |
| Zhang, Feng; Zarkada, Georgia; Han, Jinah et al. (2018) Lacteal junction zippering protects against diet-induced obesity. Science 361:599-603 |
| Hauser, Ronald G; Quine, Douglas B; Ryder, Alex et al. (2018) Unit conversions between LOINC codes. J Am Med Inform Assoc 25:192-196 |
| Juchem, Kathryn W; Sacirbegovic, Faruk; Zhang, Cuiling et al. (2018) PD-L1 Prevents the Development of Autoimmune Heart Disease in Graft-versus-Host Disease. J Immunol 200:834-846 |
| Gibb, David R; Liu, Jingchun; Natarajan, Prabitha et al. (2017) Type I IFN Is Necessary and Sufficient for Inflammation-Induced Red Blood Cell Alloimmunization in Mice. J Immunol 199:1041-1050 |
| Natarajan, Prabitha; Liu, Jingchun; Santhanakrishnan, Manjula et al. (2017) Bortezomib decreases the magnitude of a primary humoral immune response to transfused red blood cells in a murine model. Transfusion 57:82-92 |
| Sweet, Rebecca A; Nickerson, Kevin M; Cullen, Jaime L et al. (2017) B Cell-Extrinsic Myd88 and Fcer1g Negatively Regulate Autoreactive and Normal B Cell Immune Responses. J Immunol 199:885-893 |
| Iwasaki, Akiko; Foxman, Ellen F; Molony, Ryan D (2017) Early local immune defences in the respiratory tract. Nat Rev Immunol 17:7-20 |
| Uraki, Ryuta; Jurado, Kellie Ann; Hwang, Jesse et al. (2017) Fetal Growth Restriction Caused by Sexual Transmission of Zika Virus in Mice. J Infect Dis 215:1720-1724 |
| Gettinger, Scott; Choi, Jungmin; Hastings, Katherine et al. (2017) Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer. Cancer Discov 7:1420-1435 |
Showing the most recent 10 out of 134 publications
